Conditions
Neuromuscular Blockade
Trial Purpose
This study will evaluate the efficacy, safety, and pharmacokinetics (PK) of sugammadex (MK-8616) for reversal of both moderate and deep neuromuscular blockade (NMB) in pediatric participants aged birth to <2 years. The primary hypothesis of this study is that sugammadex is superior to neostigmine in reversing moderate NMB as measured by time to neuromuscular recovery.
NATIONAL TRIAL REFERENCE NUMBER
NCT03909165
When you talk with your doctor or clinical trial team member, please have the trial identifier number available.
Resources
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Age Range
0 - 2
Sex
All
About the trial
Current trial phase
Trial Phase 4
Phase 4 trials happen after a new treatment has been approved by government and health authorities. Researchers study how well a treatment works in a larger group of people and how safe it is. They gather information from thousands of people who use the treatment in a real-world setting.
Trial start and end dates
- Trial start date July 23, 2019
- Estimated primary completion date August 31, 2023
- Estimated trial completion date August 31, 2023
Trial locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
What can you do next?
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
Taking part in a clinical trial is an important decision
If you are considering joining a clinical trial, first learn as much as you can about:
- The investigational treatment that is being studied
- What the risks and possible benefits are for participants
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about